Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Prevention of Alzheimer's disease

Full Text:

About the Author

V. A. Parfenov

Russian Federation


1. <div><p>Парфенов В.А.. Спастичность В кн.: Применение ботокса (токсина ботулизма типа А) в клинической практике: руководство для врачей. Под ред. О.Р. Орловой, Н.Н. Яхно. М.: Каталог, 2001;91-122.</p><p>Ward A.B. A summary of spasticity management - a treatment algorithm. Eur J Neurol 2002;9(Suppl. 1):48-52.</p><p>Gallichio J.E. Pharmacologic management of spasticity following stroke. Phys Ther 2004;84:973-81</p><p>O'Brien C.F., Seeberger L.C., Smith D.B. Spasticity after stroke. Epidemiology and optimal treatment. Drugs Aging 1996;9:332-40.</p><p>Bakheit A.M., Thilmann A.F., Ward A.B. et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-6.</p><p>Bayram S., Sivrioglu K., Karli N. et al. Low-dose botulinum toxin with short-term electrical stimulation in poststroke spastic drop foot: a preliminary study. Am J Phys Med Rehabil 2006;85:75-81.</p><p>Ozcakir S., Sivrioglu K. Botulinum toxin in poststroke spasticity. Clin Med Res 2007;5:132-8.</p><p>Francisco G.F., Boake C. Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. Arch Phys Med Rehabil 2003;84:1194-9.</p><p>Ivanhoe C.B., Francisco G.E., McGuire J.R. et al. Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil 2006;87:1509-15.</p><p>Taira T., Hori T. Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. Acta Neurochir Suppl 2007;97:227-9</p><p>Chou R., Peterson K., Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manag 2004;28:140-75.</p><p>Gelber D.A., Good D.C., Dromerick A. et al. Open-Label Dose-Titration Safety and Efficacy Study of Tizanidine Hydrochloride in the Treatment of Spasticity Associated With Chronic Stroke. Stroke 2001;32:1841-6.</p><p>Meythaler J.M., Guin-Renfroe S., Johnson A. et al. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehabil 2001;82:1155-63.</p><p>Melka A., Haimanot R.T. Tolperisone HCl (Mydocalm): A Randomized Doubleblind and Placebo Controlled Drug Trial. International Conference on Lathyrus and Lathyrism (Book of Abstracts), 1995, Addis Abeba, Ethiopia; 31-2.</p><p>Stamenova P., Koytchev R., Kuhn K. et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. Eur J Neurol 2005;12:453-61.</p><p>Dulin J., Kovacs L., Ramm S. et al. Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective, randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 1998;31:137-42. 16.</p></div><br />


For citations:

Parfenov V.A. Prevention of Alzheimer's disease. Neurology, Neuropsychiatry, Psychosomatics. 2011;3(3):8-13. (In Russ.)

Views: 738

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)